Integrated Diagnostics Holdings

Website: Integrated Diagnostics Holdings
Index: Main Market
EPIC: IDHC
Supersector:
Sector:
Subsector:
Market Cap: £257.12M
Payout Frequency: -

Integrated Diagnostics Holdings Dividend Analysis and Summary

Declared Dividend

Key Dates

Scale and Payout

EGP equivalent payout: ˜ EGP 235m
Payout vs earnings: ˜ 18–19% of FY25 earnings (EGP 235m vs reported net profit EGP 1,302m; ˜ 19% of adjusted net profit EGP 1,262m)
Cash flow cover: Dividend ˜ 12% of FY25 operating cash flow (EGP 1,904m)
Balance sheet: Year-end net cash EGP 472m (positive even after leases), cash and financial assets EGP 2,090m

Context vs Prior Distribution

Last cash dividend paid (FY24 distribution paid in 2025): USD 0.017/share. The new proposal halves the per-share payout to USD 0.0085, consistent with Board’s “prudent” stance amid geopolitics and growth investment.

Dividend Sustainability and Growth Outlook

Operating performance supports the dividend: Revenue +37% to EGP 7.9bn; EBITDA +61% to EGP 2.74bn (34.9% margin); adjusted net profit +79% to EGP 1.26bn.
Cash generation robust: EGP 1.90bn operating cash flow; cash up by EGP 500m in FY25 despite capex and acquisition outflows.
Low payout ratio and strong cover (earnings and cash) indicate high sustainability of the proposed distribution on current metrics.
Growth trajectory: Despite strong earnings momentum, the Board is intentionally conservative; the 50% cut vs last year signals a flexible, investment-led policy more than a capacity constraint.
Competing claims on cash: Active expansion (capex additions EGP 876m) and the Cairo Ray for Radiotherapy acquisition (EGP 400m consideration) suggest ongoing reinvestment priority that could cap near-term dividend growth.

Capital Allocation and Structural Changes with Dividend Implications

M&A/Expansion: Acquisition of Cairo Ray (June 2025) broadens higher-value services (radiotherapy); continued KSA roll-out (now 100% owned after buying out Izhoor in Dec-2024). These initiatives support long-term earnings but require capital.
Financing: New medium-term loan (KFH) of EGP 400m for radiotherapy; drawdown EGP 340m by year-end. Leverage remains modest with a net cash position overall; covenants reported as compliant.
Shareholder base change: Actis’ 21.67% stake transferred to an Elliott-managed SPV (completed 9 Apr 2026). A new influential shareholder could shape future dividend policy (potentially favoring disciplined capital returns, but not yet stated).
Prior buyback (2024) and treasury share cancellation completed; no share consolidation disclosed.

Risks and Flags Relevant to Dividend Stability

FX and repatriation risk: Dividends are paid in USD; while FX availability improved in 2024–25, repatriation from Egypt could face future administrative or market constraints.
Geopolitical exposure: Heightened regional tensions (U.S.-Israel-Iran escalation) could affect Egypt/Jordan/KSA operating backdrops and external balances, influencing Board prudence on payouts.
Concentration: Egypt accounts for ~85% of revenue and ~91% of adjusted EBITDA—country risk remains the key structural exposure.
Put options: In-the-money put over Biolab (Jordan) and a put at Echo-Scan (Nigeria) represent potential future cash outlays if exercised.
Tax and FX headwinds: Effective tax rate elevated to 39% in FY25; FX loss recorded in FY25 vs a gain in FY24—both can affect distributable profit visibility.

Dividends Used in Calculation:

Ex-Dividend Date	Payment Date	Type	Amount	Currency

Total (Annual Dividends Per Share): 0.00p

Dividend Yield = Annual Dividends Per Share (0.00p) ÷ Share Price (0.58p) = 0%

Ex Dividend Date	Payment Date	Type	Amount	Currency
28/05/2026	22/06/2026	Final	0.85¢	USX
11/09/2025	03/10/2025	Interim	1.70¢	USX

Year

Number of Shares:

Payment	Paid	Amount
Next	–	–
Previous	–	–